CYTOF — Altamira Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $0.38m
- $0.74m
- $0.18m
- 40
- 82
- 16
- 43
Annual cashflow statement for Altamira Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | C2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F/A |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | fx Final | fx Final | fx Final | fx Final | fx Final |
| Net Income/Starting Line | -6.68 | -8.74 | -18.7 | -27.8 | -1.98 |
| Depreciation | |||||
| Non-Cash Items | -0.572 | 3.24 | 3.42 | 13.9 | -0.11 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -1.23 | 0.32 | 0.196 | 4.71 | 1.52 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -8.45 | -5.16 | -15 | -9.1 | -0.575 |
| Capital Expenditures | -3.04 | -2.47 | -3.64 | -2.24 | — |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 0.018 | 0 | -0.196 | 0.001 | 0.002 |
| Sale of Fixed Assets | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -3.02 | -2.47 | -3.83 | -2.24 | 0.002 |
| Financing Cash Flow Items | -0.959 | -0.679 | -0.176 | -0.058 | 1.11 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 7.43 | 18.1 | 7.24 | 10.3 | 1.11 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -4.03 | 10.5 | -11.2 | -1.01 | 0.54 |